3, 2, 1! From GLP-2 to GLP-1 analog over a 10-year journey.

Short bowel syndrome (SBS) represents one of the central conditions in clinical nutrition, with a complex and challenging management. Teduglutide, an analog of human glucagon-like peptide-2 (GLP-2), is the first approved long-term, non-symptomatic treatment for SBS. We present the case of a 62-year-old woman with SBS who required prolonged home parenteral nutrition (HPN). Following clinical stabilization, teduglutide was initiated, leading to significant clinical and nutritional improvement, including spontaneous closure of enterocutaneous fistulas and a 70% reduction in parenteral nutrition requirements. This allowed for a surgical reconstruction, after which she achieved full enteral autonomy, later developing grade 1 obesity. This case highlights the therapeutic potential of teduglutide as a bridging therapy and the remaining uncertainties regarding its long-term management.